Literature DB >> 3052052

New perspectives on the pathogenesis of rheumatoid arthritis.

N J Zvaifler1.   

Abstract

In the pathogenesis of rheumatoid arthritis, locally produced antibodies complex with an inciting antigen, yet to be identified, within the joint and activate the complement system, resulting in articular inflammation mediated primarily by polymorphonuclear leukocytes and their products. Chronic inflammatory cells then produce soluble factors that induce both tissue destruction and inflammation. A major issue is how and why apparently normal immune responses in the acute stage progress to chronic inflammation in subsequent months to years. Although it is often assumed that the initial etiologic agent, persisting in the joint or at an extra-articular site, is responsible for continued synovitis, this need not be the case. It is possible that once the inciting agent is cleared from the joint through a normal immune response, the presence of activated cells rich in surface class II histocompatibility (Ia) antigens could, under the influence of multiple genetic or environmental factors, become the target of autoimmune attack. Alternatively, the process might result from the interactions of synovial lining cells and their products with T cells assuming a secondary role. Further research into the relative contributions of soluble products, T helper and suppressor subsets, synoviocytes, and antigen determine which model is correct.

Entities:  

Mesh:

Year:  1988        PMID: 3052052      PMCID: PMC7119386          DOI: 10.1016/0002-9343(88)90356-7

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  30 in total

1.  Identification of immunostimulatory dendritic cells in the synovial effusions of patients with rheumatoid arthritis.

Authors:  N J Zvaifler; R M Steinman; G Kaplan; L L Lau; M Rivelis
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

Review 2.  The autoimmune diseases.

Authors:  J J Condemi
Journal:  JAMA       Date:  1987-11-27       Impact factor: 56.272

3.  Isolation of an interleukin-1-like factor from human joint effusions.

Authors:  D D Wood; E J Ihrie; C A Dinarello; P L Cohen
Journal:  Arthritis Rheum       Date:  1983-08

Review 4.  Cellular immunity in the joints of patients with rheumatoid arthritis and other forms of chronic synovitis.

Authors:  G S Firestein; V Tsai; N J Zvaifler
Journal:  Rheum Dis Clin North Am       Date:  1987-08       Impact factor: 2.670

Review 5.  Pathways to chronic inflammation in rheumatoid synovitis.

Authors:  D Cavender; D Haskard; C L Yu; T Iguchi; P Miossec; N Oppenheimer-Marks; M Ziff
Journal:  Fed Proc       Date:  1987-01

6.  Immune function in severe, active rheumatoid arthritis. A relationship between peripheral blood mononuclear cell proliferation to soluble antigens and synovial tissue immunohistologic characteristics.

Authors:  D G Malone; S M Wahl; M Tsokos; H Cattell; J L Decker; R L Wilder
Journal:  J Clin Invest       Date:  1984-10       Impact factor: 14.808

7.  Inhibitor of interleukin-2 in rheumatoid synovial fluid.

Authors:  P Miossec; T Kashiwado; M Ziff
Journal:  Arthritis Rheum       Date:  1987-02

8.  Spirochetal antigens and lymphoid cell surface markers in Lyme synovitis. Comparison with rheumatoid synovium and tonsillar lymphoid tissue.

Authors:  A C Steere; P H Duray; E C Butcher
Journal:  Arthritis Rheum       Date:  1988-04

9.  Production of a cytokine with interleukin 3-like properties and cytokine-dependent proliferation in human autologous mixed lymphocyte reaction.

Authors:  R Suzuki; S Suzuki; T Takahashi; K Kumagai
Journal:  J Exp Med       Date:  1986-11-01       Impact factor: 14.307

10.  Characterization of the killer cell generated in the autologous mixed leukocyte reaction.

Authors:  M Goto; N J Zvaifler
Journal:  J Exp Med       Date:  1983-04-01       Impact factor: 14.307

View more
  6 in total

1.  A novel combination of methotrexate and epigallocatechin attenuates the overexpression of pro-inflammatory cartilage cytokines and modulates antioxidant status in adjuvant arthritic rats.

Authors:  Souvik Roy; Santanu Sannigrahi; Ram Prasad Vaddepalli; Balaram Ghosh; Priyanka Pusp
Journal:  Inflammation       Date:  2012-08       Impact factor: 4.092

2.  Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. A novel approach to immunosuppressive therapy.

Authors:  C J Carrera; C Terai; M Lotz; J G Curd; L D Piro; E Beutler; D A Carson
Journal:  J Clin Invest       Date:  1990-11       Impact factor: 14.808

3.  Basement membrane proteins in synovial membrane: distribution in rheumatoid arthritis and synthesis by fibroblast-like cells.

Authors:  M Schneider; B Voss; J Rauterberg; M Menke; T Pauly; R K Miehlke; J Friemann; U Gerlach
Journal:  Clin Rheumatol       Date:  1994-03       Impact factor: 2.980

Review 4.  B lymphocytes and humoral immune responses in rheumatoid arthritis.

Authors:  L S De Clerck
Journal:  Clin Rheumatol       Date:  1995-09       Impact factor: 2.980

5.  Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine.

Authors:  D A Carson; D B Wasson; L M Esparza; C J Carrera; T J Kipps; H B Cottam
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205

6.  Piroxicam-induced hepatic and renal histopathological changes in mice.

Authors:  Hossam Ebaid; Mohamed A Dkhil; Mohamed A Danfour; Amany Tohamy; Mohamed S Gabry
Journal:  Libyan J Med       Date:  2007-06-01       Impact factor: 1.657

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.